NCT00467428 is a Phase 2 clinical trial of NS2359 in Attention Deficit Hyperactivity Disorder, sponsored by NeuroSearch A/S.

Who is sponsoring NCT00467428?

NCT00467428 is sponsored by NeuroSearch A/S.

What drugs are being tested in NCT00467428?

Interventions in NCT00467428: NS2359, Placebo.

What condition does NCT00467428 study?

NCT00467428 studies Attention Deficit Hyperactivity Disorder.

Is NCT00467428 still recruiting?

NCT00467428 is currently completed. Last updated 27 April 2007.

Last reviewed 2007-04-27 · How we verify

NCT00467428

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder. A Randomised, Double-Blind, Placebo-Controlled Study

Completed Phase 2 Last updated 27 April 2007

What this trial tests

Phase 2 trial testing NS2359 in Attention Deficit Hyperactivity Disorder in 126 participants. Completed in 1 September 2004.

Timeline

1 August 2003

1 September 2004

Quick facts

Lead sponsor	NeuroSearch A/S
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	126
Start date	1 August 2003
Estimated completion	1 September 2004
Sites	1 location across United States

Drugs / interventions tested

NS2359 — full drug profile →
Placebo

Conditions studied

Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →

Sponsor

NeuroSearch A/S — full company profile →

Who can join

Adults 18 to 55, any sex, with Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To investigate the efficacy of NS2359 in adult patients diagnosed with ADHD (predominantly inattentive, predominantly hyperactive/impulsive or combined) according to DSM-IV criteria.

Sponsor's own description

The purpose of the study is to investigate if NS2359 is effective in the treatment of ADHD in adult patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Attention Deficit Hyperactivity Disorder

Currently open trials in the same condition.

NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
NCT06847165 — Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure · NA · recruiting
NCT06325813 — ADHD PreSMA Response Inhibition Therapy · NA · recruiting
NCT06248229 — A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder · Phase 4 · recruiting
NCT06232226 — Attention Deficit Hyperactivity Disorder · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00467428 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NeuroSearch A/S
Last refreshed: 27 April 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00467428.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing